ARHGEF25

Across TCGA pan-cancer cohorts, ARHGEF25 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ARHGEF25’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ARHGEF25 RNA is repressed in tumor relative to normal tissue. In most cancer types ARHGEF25 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

BLCA, KICH, and COAD are the cancer types where ARHGEF25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−2.041	<.001	8	view →
KICH	Female	All	−1.942	<.001	8	view →
COAD	Male	All	−1.506	<.001	8	view →
HNSC	All	II,III,IV	+0.694	.002	7	view →
UCEC	All	All	−2.587	<.001	6	view →
BRCA	Female	All	−0.841	<.001	6	view →
STAD	All	All	−1.426	.001	5	view →
READ	All	All	−2.442	.001	4	view →
CHOL	All	All	+1.994	<.001	3	view →
LIHC	Female	All	+0.670	.001	3	view →
LUAD	All	All	−0.325	.015	3	view →
PRAD	All	All	−1.159	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ARHGEF25–BLCA

Open the BLCA breakdown →